Recent Progress of Oridonin and Its Derivatives for the Treatment of Acute Myelogenous Leukemia
Volume: 20, Issue: 6, Pages: 483 - 497
Published: May 11, 2020
Abstract
First stage human clinical trial (CTR20150246) for HAO472, the L-alanine-(14-oridonin) ester trifluoroacetate, was conducted by a Chinese company, Hengrui Medicine Co. Ltd, to develop a new treatment for acute myelogenous leukemia. Two patents, WO2015180549A1 and CN201410047904.X, covered the development of the I-type crystal, stability experiment, conversion rate research, bioavailability experiment, safety assessment, and solubility study....
Paper Details
Title
Recent Progress of Oridonin and Its Derivatives for the Treatment of Acute Myelogenous Leukemia
Published Date
May 11, 2020
Volume
20
Issue
6
Pages
483 - 497
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History